Abstract
Introduction: Among Non-Hodgkin lymphomas (NHL), DLBCL is the most prevalent subtype (~30% of diagnoses). First-line (1L) chemoimmunotherapy cures many patients (pts), but 30-40% will relapse. Prognostic and predictive biomarkers are needed to identify pts refractory to 1L therapy or at high risk of relapse, enabling timely intervention and improved outcomes. This study evaluated tumor-informed WGS-based longitudinal ctDNA monitoring in a real-world DLBCL cohort.
Methods: We retrospectively analyzed ctDNA data from 49 pts with DLBCL. Plasma samples were collected before, during, and at the end of 1L therapy (EOT, defined as ± 21 days from the last infusion (preferred when available) or ± 14 days from post-treatment PET imaging) and during surveillance/subsequent treatments. A WGS-based tumor-informed assay (Signatera™ Genome, Natera, Inc.) was used for ctDNA detection and quantification. The association of ctDNA dynamics with event-free survival (EFS) was evaluated using Cox regression analysis, restricted to pts completing at least 5 cycles of 1L therapy.
Results: The median age of the cohort was 62 years (range: 56-74), and median follow-up was 22 months (range: 14-30). Pre-treatment ctDNA-positivity rate was 100% (31/31). A total of 19 pts achieved ctDNA clearance during 1L therapy (early clearance within 3 cycles, n=5; late clearance between cycle 4 and EOT, n=14). Pts with no clearance or ctDNA-positivity at EOT (n=7) had significantly inferior EFS compared to those achieving ctDNA clearance (HR 8.04, 95%CI: 1.87-34.62, p=0051). On further stratifying the clearance group and comparing with no clearances, pts with early clearance had superior outcomes (HR 13.22, 95%CI: 1.48-1741.94, p=0.0166), relative to late clearances (HR 5.65, 95%CI 1.46–25.16, p=0.0129). Notably, all 5 pts with early ctDNA clearance remained serially negative and relapse-free. Of the 49 pts, 9 proceeded to chimeric antigen receptor T-cell therapy (CAR-T). Among 6 of these pts with available ctDNA results pre and post therapy, all 3 who stayed ctDNA-positive after CAR-T relapsed (1.3, 2, and 4.5 months post-infusion); 1 pt with pre- and post-CAR-T ctDNA-negativity and 2 pts with ctDNA clearance post-CAR-T remained relapse-free for 9.6, 15.9, and 22.4 months, respectively. Taken together, the PPV and NPV for a single ctDNA time point post CAR-T infusion were 100% for predicting long-term clinical outcomes.
Conclusions: Our data support longitudinal ctDNA monitoring as a valuable prognostic and predictive biomarker in DLBCL. ctDNA clearance, particularly early clearance within the first 3 cycles of 1L therapy, is associated with improved pt outcomes. Longitudinal ctDNA monitoring and dynamics can enable identification of high-risk pts who do not clear ctDNA and may benefit from earlier referral for CAR-T. Furthermore, ctDNA monitoring pre- and post-CAR-T infusion is predictive of treatment response and can identify pts at high risk of relapse.
